CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biopharmaceutical company, announced today that Dr. Spyridon "Spyros" Papapetropoulos has joined as Executive Vice President, Research and Development and Chief Medical Officer. Dr. Papapetropoulos will lead Cavion’s research and development organization to advance therapies based on the company’s T-type calcium channel (Cav3) platform.
“Spyros joins the Cavion team at an exciting time. He is an experienced leader with a passion for conducting innovative trials that deliver new treatment options to patients with neurological diseases with limited treatment options,” said Cavion CEO and President Andrew Krouse. He added, “Spyros will help extend Cavion’s presence in the Boston/Cambridge area.”
Dr. Papapetropoulos noted, “Cavion’s selective Cav3 modulating platform, which includes best-in-class clinical stage compounds, is expected to restore rhythmic neuronal firing in brain regions associated with a variety of chronic neurological diseases.” He added, “I look forward to working closely with Cavion’s team to apply innovative but empathetic approaches to achieving clinical breakthroughs. Our end goal is to bring safe, effective and accessible treatments to people with chronic neurological diseases, quickly and efficiently.”
Dr. Papapetropoulos has extensive academic, biopharmaceutical and digital health experience, most recently serving as Vice President, Global Specialty Development, Neurodegenerative Diseases, Movement Disorders and Clinical Trial Innovation for Teva Pharmaceutical Industries Ltd. Prior to Teva, he managed neuroscience research and medical affairs programs at Pfizer Inc., Allergan Inc., and Biogen Idec Inc. Dr. Papapetropoulos has overseen a wide spectrum of pharmaceutical development programs from regulatory filing to new product launch. He holds appointments as consultant with Massachusetts General Hospital and voluntary Professor of Neurology with the University of Miami, Miller School of Medicine.
About Cavion, Inc.
Cavion, Inc. is a privately held clinical stage biotechnology company creating therapies modulating the T-type calcium channel (Cav3) for the treatment of neurological diseases. Cavion’s platform of Cav3 modulators restore the brain’s natural rhythms in a variety of chronic neurological diseases such as essential tremor, Parkinson’s disease, neuropathic pain, and epilepsy as well as orphan and rare neuro-developmental and genetic disorders.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Cavion, Inc. disclaims any intent or obligation to update forward-looking statements, except as required by law.
